Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2022 | The use of tafasitamab and lenalidomide in R/R DLBCL

Umberto Vitolo • 12 Dec 2022
ASH 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Tafasitamab
L-MIND

Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, comments on the mechanism of action and efficacy of tafasitamab alone or in combination with other agents such as rituximab and lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting data from the L-MIND study (NCT02399085). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Seagen, Genmab, Incyte, Costellation, Bayer, Regeneron: Consultancy; AbbVie, Incyte, Janssen, Gilead Sciences: Speakers Bureau.

More from Umberto Vitolo

Outcomes from the EPCORE DLBCL-3 trial: fixed-duration epcoritamab in elderly patients with DLBCL
2:36
Outcomes from the EPCORE DLBCL-3 trial: fixed-duration epcoritamab in elderly patients with DLBCL
Umberto Vitolo • 12 Jun 2026
Will frontline DLBCL treatment become subtype-specific rather than a one-regimen-fits-all approach?
1:12
Will frontline DLBCL treatment become subtype-specific rather than a one-regimen-fits-all approach?
Umberto Vitolo • 12 Jun 2026
Results from the Phase III FRONTMIND study: tafasitamab, lenalidomide, and R-CHOP in frontline DLBCL
2:16
Results from the Phase III FRONTMIND study: tafasitamab, lenalidomide, and R-CHOP in frontline DLBCL
Umberto Vitolo • 12 Jun 2026
Fixed-duration epcoritamab with BR for 1L treatment of FL: 3-year results from EPCORE NHL-2 arm 3
1:39
Fixed-duration epcoritamab with BR for 1L treatment of FL: 3-year results from EPCORE NHL-2 arm 3
Umberto Vitolo • 5 Dec 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals